EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence

Hiroyoshi Suzuki iD, Shusuke Akamatsu, Masaki Shiota iD, Haruka Kakiuchi, Takahiro Kimura iD

International Journal of Urology · 2025

DOI: 10.1111/iju.15647 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Urology, 2025. Verfasst von Hiroyoshi Suzuki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Toho University Sakura Medical Center, Chiba, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Combined Chemotherapy Protocols, Androgen Antagonists, Androgen Receptor Antagonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer Yakuhin Ltd., Bayer Yakuhin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) growth is hormone‐dependent and it frequently develops distant metastases as disease progresses. Patients with metastatic castration‐sensitive prostate cancer (mCSPC) initially respond to androgen deprivation therapy (ADT) but eventually become refractory and develop metastatic castration‐resistant prostate cancer (mCRPC). Castration‐resistance is associated with high lethality and metastases confer poor prognosis, therefore unmet needs in treatment for mCSPC remain high. So far, improvements in survival in mCSPC have been achieved by doublet combination therapy such as docetaxel or an androgen‐receptor signaling inhibitor (ARSI) in addition to ADT. Further, recent phase 3 trials have shown that triplet therapy—a combination of ARSI, docetaxel, and ADT improves prognosis compared with docetaxel plus ADT in mCSPC. PC tumors manifest intra‐ and inter‐tumoral heterogeneity at both the genetic and phenotypic level. As heterogeneity increases during sequential treatment and disease progression, it is reasonable to initiate combination therapy using drugs with different mechanisms of action early in the course of disease, such as mCSPC. Previous research about tumor heterogeneity and drug resistant mechanism support this rationale, as well as preclinical studies and real‐world data provide the scientific evidence of benefit by combining ARSI and docetaxel. Here, we review the rationale and clinical evidence for triplet therapy in patients with mCSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntineoplastic Combined Chemotherapy ProtocolsAndrogen AntagonistsAndrogen Receptor AntagonistsHumansMaleDocetaxelDisease ProgressionNeoplasm Metastasis

Stichwörter der Autor:innen

androgen receptor signaling inhibitordocetaxelmetastatic castration‐sensitive prostate cancerprostate cancertriplet therapy

Substanzen

DocetaxelAndrogen AntagonistsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Urology, Toho University Sakura Medical Center, Chiba, Japan.
  • Department of Urology, Nagoya University, Nagoya, Japan.
  • Department of Urology, Kyushu University, Fukuoka, Japan.
  • Oncology Medical Affairs, Medical Affairs and Pharmacovigilance, Bayer Yakuhin Ltd., Osaka, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

ORCID-Profile: Hiroyoshi Suzuki, Masaki Shiota, Takahiro Kimura

Förderung

  • Bayer Yakuhin Ltd.
  • Bayer Yakuhin

Zitieren

APA

Suzuki, H., Akamatsu, S., Shiota, M., Kakiuchi, H., & Kimura, T. (2025). Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence. International Journal of Urology. https://doi.org/10.1111/iju.15647

Vancouver

Suzuki H, Akamatsu S, Shiota M, Kakiuchi H, Kimura T. Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence. International Journal of Urology. 2025. doi:10.1111/iju.15647

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Hiroyoshi and Akamatsu, Shusuke and Shiota, Masaki and Kakiuchi, Haruka and Kimura, Takahiro},
  title = {Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.15647}
}
Kostenlos starten →